The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.
June 17th 2024
Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.
Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation